U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07935733) titled 'Blood Biomarkers for Prognostic Stratification in Guillain-Barre Syndrome' on Oct. 21.
Brief Summary: Guillain-Barre syndrome (GBS) is an acute immune-mediated peripheral neuropathy characterized by substantial variability in clinical severity, functional recovery, and pain outcomes. The lack of validated and accessible prognostic biomarkers limits early risk stratification and individualized rehabilitation strategies.
This observational, longitudinal, retrospective and prospective study aims to evaluate a panel of five blood biomarkers (EGR1, EGR2, GBP1, miR-29c, and Piccolo) and determine their association with functional recover...